Compare Neurocrine Biosciences Inc (NBIX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Texas Instruments Incorporated — how do they compare? Neurocrine Biosciences Inc trades at $156.69 (market cap $16.76B), while Texas Instruments Incorporated trades at $284.1 (market cap $256.11B). The key difference: Texas Instruments Incorporated is far larger — about 15.3× Neurocrine Biosciences Inc's market cap, and Texas Instruments Incorporated pays a 2.03% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TXN | |
|---|---|---|
Market Cap | $16.76B | $256.11B |
Sector | Health | Technology |
52-Week High | $185.50 | $332.35 |
52-Week Low | $123.10 | $153.33 |
Enterprise Value | $16.78B | $263.16B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Texas Instruments (TXN) trades at $281.24, down 1.69% over 24 hours, with a bullish technical signal from moving averages and recent price action above the 20-day average. Revenue grew to $17.68 billion in 2025, with net income of $5.00 billion and strong profitability margins. Recent news highlights CFO transition and AI-driven demand boosting data center revenue.
Outlook remains positive with analyst consensus price target of $333.10, implying 18% upside. Risks include high valuation multiples and increasing debt-to-asset ratio. The stock presents opportunity from AI infrastructure growth but faces margin pressure and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
